Veritas In Silico Inc. (JP:130A) has released an update.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Veritas In Silico Inc. is expanding its global reach by securing a patent in Europe for its innovative method in RNA-targeted drug discovery. This strategic move is expected to enhance their proprietary drug discovery platform, ibVIS®, despite the patent having a minimal immediate impact on business performance. The company anticipates significant future progress from this development.
For further insights into JP:130A stock, check out TipRanks’ Stock Analysis page.